| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3234 | Maropitant Citrate [359875-09-5] Featured | Neurokinin receptor antagonist with antiemetic activity |
|
| DCC3235 | Massiliamide | Novel potent tyrosinase inhibitor from the Gram-negative bacterium Massilia albidiflava DSM 17472T |
|
| DCC3236 | May1-in-13a | Novel potent inhibitor of May1 with Ki = 12 ± 1 nM, also inhibiting wild-type HIV-1 protease with Ki = 32 ± 5 pM and three drug resistance-associated mutants with Ki values ranging from 24 to 320 pM |
|
| DCC3237 | Maysin | Natural Anti-inflammation Agent, Attenuating Amyloid Plaques by Inducing Humoral Immune Response with Th2 Skewed Cytokine Response in the Tg (APPswe, PS1dE9) Alzheimer's Mouse Model |
|
| DCC3238 | Mb-001 | Novel potent inhibitor of the membrane-bound retinoid isomerase RPE65 |
|
| DCC3239 | Mb06322 | Prodrug of MB05032, acting as potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes |
|
| DCC3240 | Mb16695 | Novel Inhibitor of Mycobacterium tuberculosis α-1,4-Glucan Branching Enzyme (GlgB) |
|
| DCC3241 | Mb-211 | Novel inhibitor of dengue and West Nile virus NS2B-NS3 protease |
|
| DCC3242 | Mbls-in-5 | Novel non-hemolytic and low toxic inhibitor of metallo-β-lactamases (MBLs), restoring the activity of meropenem against Escherichia coli, Citrobacter freundii, Proteus mirabilis and Klebsiella pneumonia, which carried resistance genes of blaNDM-1 |
|
| DCC3243 | Mbp-c12 | Novel detergent, showing enhanced stability to all tested proteins compared to a gold standard detergent (DDM) |
|
| DCC3244 | Mbp-c9 | Novel detergent, showing enhanced stability to all tested proteins compared to a gold standard detergent (DDM) |
|
| DCC3245 | Mbri-001 | Deuterium-substituted anticancer agent, plinabulin, exhibiting better pharmacokinetic characteristics than that of plinabulin |
|
| DCC3246 | Mbt-fh Inhibitor-7 | The first selective small molecule inhibitor of the Mycobacterium tuberculosis fumarate hydratase |
|
| DCC3247 | Mbx-1066 | Potent antibacterial agent against a wide range of Gram-positive and Gram-negative bacteria |
|
| DCC3248 | Mbx-1162 | Novel antibacterial agent, remarkably potent against antibiotic-resistant bacterial strains such as MDR A. baumannii , ESBL-producing Klebsiella pneumoniae, VRE, and MRSA |
|
| DCC3249 | Mbx-1887 | Antibacterial agent, with a relatively narrow spectrum against bacteria and a very high CC 50 value |
|
| DCC3250 | Mbx2546 | Novel specific inhibitor of HA-mediated viral entry, inhibiting HPAI H5N1 virus strain A/Hong Kong/H5N1 |
|
| DCC3251 | Mc1220 | Topical nonnucleoside reverse transcriptase inhibitor, partially preventing vaginal RT-SHIV infection of macaques |
|
| DCC3252 | Mc-1353 | Potent and HDAC class I-selective inhibitor |
|
| DCC3253 | Mc1420 | Novel potent acetylcholinesterase (AChE) inhibitor |
|
| DCC3254 | Mc-1-f2 | The first inhibitor of forkhead Box Protein C2 (FOXC2) |
|
| DCC3255 | Mc2050 | Novel selective PARP1 inhibitor, inhibitng apoptosis and blocking poly ADP-ribosylation of histone H1 in hydrogen peroxide treated SH-SY5Y neuroblastoma cells |
|
| DCC3256 | Mc2392 | Novel hybrid retinoid-HDAC inhibitor |
|
| DCC3257 | Mc-70 Hydrochloride | Potent P-gp inhibitor with good selectivity towards BCRP pump (EC50 values 0.05 μM, 0.69 μM, 9.3 μM, and 73 μM for Caco-2, MDR1, MRP1, and BCRP inhibition, respectively) |
|
| DCC3258 | Mca-13 | Novel neurotropic agent |
|
| DCC3259 | Mca-yvadapk(dnp)-oh | Specific and highly fluorescent substrate for caspase-1, also acting as a substrate for caspase-4 |
|
| DCC3260 | Mcc1019 | Novel selective inhibitor of the Polo-box domain of Polo-like kinase 1 (PLK1) |
|
| DCC3261 | Mcc1189 | First-in-class inhibitor of MFS efflux pump CaMdr1p |
|
| DCC3262 | Mcc-134 | Novel inverse agonist for the pancreatic-type ATP-sensitive K channel as vascular relaxing agent |
|
| DCC3263 | MCC950 free acid Featured | Potent and selective inhibitor of NLRP3, reducing interleukin-1β (IL-1β) production in vivo and attenuating the severity of experimental autoimmune encephalomyelitis (EAE) |
|
